Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
Détails
ID Serval
serval:BIB_75E5C403C413
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
Périodique
Clinical pharmacology and therapeutics
ISSN
0009-9236
Statut éditorial
Publié
Date de publication
1999
Peer-reviewed
Oui
Volume
66
Numéro
1
Pages
76-84
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
PURPOSE: To compare the renal hemodynamic and tubular effects of celecoxib, a selective inhibitor of cyclooxygenase-2 (COX-2) to those of naproxen, a nonselective inhibitor of cyclooxygenases in salt-depleted subjects. METHODS AND SUBJECTS: Forty subjects were randomized into four parallel groups to receive 200 mg celecoxib twice a day, 400 mg celecoxib twice a day, 500 mg naproxen twice a day, or a placebo for 7 days according to a double-blind study design. Blood pressure, renal hemodynamics, and urinary water and electrolyte excretion were measured before and for 3 hours after drug intake on days 1 and 7. RESULTS: Celecoxib had no effect on systemic blood pressure, but short-term transient decreases in renal blood flow and glomerular filtration rate were found with the highest dose of 400 mg on day 1. On the first day, both celecoxib and naproxen decreased urine output (P < .05) and sodium, lithium, and potassium excretion (P < .01). On day 7, similar effects on water and sodium excretion were observed. During repeated administration, a significant sodium retention occurred during the first 3 days. CONCLUSION: In salt-depleted subjects, selective inhibition of COX-2 causes sodium and potassium retention. This suggests that an increased selectivity for COX-2 does not spare the kidney, at least during salt depletion.
Mots-clé
Adult, Blood Pressure, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Cyclooxygenase Inhibitors, Double-Blind Method, Humans, Isoenzymes, Kidney, Lithium, Male, Membrane Proteins, Naproxen, Potassium, Prostaglandin-Endoperoxide Synthases, Pyrazoles, Reference Values, Sodium, Sulfonamides, Voluntary Workers
Pubmed
Web of science
Création de la notice
05/03/2008 16:39
Dernière modification de la notice
20/08/2019 14:33